Neurodegenerative Disease News and Research

RSS

Unraveling molecular dysfunction due to environmental toxin exposure

In a new article published in the journal Molecular Neurodegeneration, researchers at the University of Missouri School of Medicine take some of the first steps toward unraveling the molecular dysfunction that occurs when proteins are exposed to environmental toxins. Their discovery helps further explain recent NIH findings that demonstrate the link between Parkinson's disease and two particular pesticides - rotenone and paraquat.

23 Jun 2011

Penn State College of Medicine researchers create brief exam that identifies cognitive changes in ALS patients

Patients with amyotrophic lateral sclerosis (ALS) could lose brain function earlier than is noticeably detectable, affecting their ability to make decisions about their care. Physicians need a method to assess these sensitive changes in brain function, without the need for extensive neuropsychological tests.

23 Jun 2011

Key trigger to rare but deadly neurodegenerative disease

Jeremy Smith, Governor's Chair for Molecular Biophysics at the University of Tennessee, Knoxville, has helped reveal a key trigger of Gerstmann-Str-ussler-Scheinker (GSS) syndrome, a rare but deadly neurodegenerative disease. The finding could have far-reaching implications for the treatment of other neurodegenerative diseases such as Alzheimer's, Huntington's, and Parkinson's.

23 Jun 2011

Scientists discover linchpin protein that drives mitochondria's calcium machinery

Mitochondria, those battery-pack organelles that fuel the energy of almost every living cell, have an insatiable appetite for calcium. Whether in a dish or a living organism, the mitochondria of most organisms eagerly absorb this chemical compound.

20 Jun 2011

Scientists discover three susceptibility genes for development of progressive supranuclear palsy

An international research team, co-led by scientists at Mayo Clinic's campus in Florida, have discovered three potential susceptibility genes for development of progressive supranuclear palsy (PSP), a rare neurodegenerative disease that causes symptoms similar to those of Parkinson's disease but is resistant to Parkinson's medications.

20 Jun 2011

New insight into progressive supranuclear palsy

There are new genetic clues on risk factors and biological causes of a rare neurodegenerative disease called progressive supranuclear palsy (PSP), according to a new study from an international genetics team led by researchers from the Perelman School of Medicine at the University of Pennsylvania.

20 Jun 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen Corporation today reported results for the fourth quarter and fiscal year 2011, ended March 31, 2011.

9 Jun 2011

Medical researchers uncover a novel approach to treat Huntington's disease

Medical researchers may have uncovered a novel approach to treat an incurable and ultimately fatal neurodegenerative disease that affects hundreds of thousands of people.

3 Jun 2011

Suberoylanilide hydroxamic acid holds promise against familial frontotemporal dementia

A drug already approved for people with cancer shows early potential as a therapy for a common form of dementia, UT Southwestern Medical Center researchers report.

1 Jun 2011

Rochester receives $1M FDA, BDRSA grant to begin first controlled clinical trial in Juvenile Batten disease

After years of building hope for a treatment, Rochester researchers and clinicians will begin the first controlled clinical trial for Juvenile Batten disease this summer, thanks to $1 million in grants from the Food and Drug Administration and the Batten Disease Support and Research Association.

1 Jun 2011

ENS, SSIF announce prestigious award to recognize excellence in medical education

Serono Symposia International Foundation (SSIF) has announced today a public competition for an Award to recognise an expert in the field of neurology who has made a significant contribution to medical education activities through research and dedication.

30 May 2011

Elan, Proteostasis create innovative drug discovery initiative for neurodegenerative disorders

Proteostasis Therapeutics and Elan Corporation today announced a strategic business relationship to advance Proteostasis' platform for the discovery and development of disease-modifying, small molecule drugs and diagnostics for the treatment of neurodegenerative disorders such as Parkinson's, Huntington's, multiple sclerosis and amyotrophic lateral sclerosis, and a broad array of dementia-related diseases including Alzheimer's.

25 May 2011

Multiple toxic mechanisms link elevated iron, copper levels in the brain and extensive DNA damage

No one knows the cause of most cases of Alzheimer's, Parkinson's and other neurodegenerative disorders. But researchers have found that certain factors are consistently associated with these debilitating conditions.

21 May 2011

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

Repligen Corporation announced today that it has received approval from the Food and Drug Administration to initiate a Phase 1 clinical trial of RG3039, a potential treatment for Spinal Muscular Atrophy.

19 May 2011

UCSD scientists discover steroid hormone that inhibits brain inflammation

Researchers at the University of California, San Diego School of Medicine have discovered a steroid hormone that inhibits inflammation in the brain. The findings, to be published in the May 13 issue of the journal Cell, have implications for understanding the exaggerated inflammatory responses that are characteristic features of numerous neurodegenerative diseases.

13 May 2011

Conference to discuss process of synaptic plasticity in Alzheimer's disease

Optimal functioning of neural networks is critical to the complex cognitive processes of memory, language, emotion and reasoning that deteriorate in people suffering from Alzheimer's disease.

12 May 2011

Being mildly overweight benefits ALS patients

Patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, may be an exception to the rule that being overweight is a health hazard. In a retrospective study of over 400 ALS patients, Massachusetts General Hospital researchers found that those who were mildly obese survived longer than patients who were normal weight, underweight or even overweight.

12 May 2011

Scientists use new technologies to identify genetic cause of Kufs disease

Scientists from the Walter and Eliza Hall Institute and the University of Melbourne have used innovative new technologies to identify the gene responsible for a rare but fatal hereditary brain disorder. The discovery will make it possible to diagnose the disease through a blood test rather than a brain biopsy.

6 May 2011

Proteostasis acquires Harvard University's two novel protein target licenses

Proteostasis Therapeutics announced today that it has acquired two exclusive licenses from Harvard University to technologies for enhancing the activity of a key cellular protein clearance mechanism, the ubiquitin-proteasome pathway.

27 Apr 2011

Repligen anticipates 30% increase in total revenues for 2011

Repligen Corporation today announced preliminary financial results for fiscal year 2011 which ended March 31, 2011. Total revenue for the year is expected to be $27.3 million compared to $21.0 million in the prior fiscal year, an increase of 30%.

21 Apr 2011

Neurodegenerative Disease News and Research

Unraveling molecular dysfunction due to environmental toxin exposure

Penn State College of Medicine researchers create brief exam that identifies cognitive changes in ALS patients

Key trigger to rare but deadly neurodegenerative disease

Scientists discover linchpin protein that drives mitochondria's calcium machinery

Scientists discover three susceptibility genes for development of progressive supranuclear palsy

New insight into progressive supranuclear palsy

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Medical researchers uncover a novel approach to treat Huntington's disease

Suberoylanilide hydroxamic acid holds promise against familial frontotemporal dementia

Rochester receives $1M FDA, BDRSA grant to begin first controlled clinical trial in Juvenile Batten disease

ENS, SSIF announce prestigious award to recognize excellence in medical education

Elan, Proteostasis create innovative drug discovery initiative for neurodegenerative disorders

Multiple toxic mechanisms link elevated iron, copper levels in the brain and extensive DNA damage

Repligen receives approval from FDA to commence RG3039 Phase 1 trial in Spinal Muscular Atrophy

UCSD scientists discover steroid hormone that inhibits brain inflammation

Conference to discuss process of synaptic plasticity in Alzheimer's disease

Being mildly overweight benefits ALS patients

Scientists use new technologies to identify genetic cause of Kufs disease

Proteostasis acquires Harvard University's two novel protein target licenses

Repligen anticipates 30% increase in total revenues for 2011

Aneuro: A Year of Neuroscience in Review eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News